Bayer Backs Eylea's Prospects Despite Lucentis Biosimilars
Market leader In Wet AMD Still Selling Strongly
Executive Summary
Competition, both branded and generic, is on the rise but the German group believes that Eylea will continue to outperform given its safety and efficacy profile and the potential of a longer-lasting version of the eye therapy.
You may also be interested in...
High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.
Europe’s Big Pharma Sails On Serenely Despite Choppy Economic Waters
The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.
Viatris Tipped To Knock Out Crucial Eylea Dosing Patents In US
A senior analyst for a major investment bank has listened to oral arguments in Viatris’ legal tussle vs. Regeneron over two key US dosing patents shielding the originator’s Eylea (aflibercept) blockbuster.